As A Botanical, Cannabidiol Was Next Ingredient Up For AHPA's Guidance On Use In Supplements
Leading discussions on CBD safety as a dietary ingredient and developing best-practices guidance were natural steps for AHPA. "We were viewing it as another botanical product, another one of the type of products that we’ve been dealing with throughout our history," said program development director Jane Wilson.
You may also be interested in...
Global nonprofit supporting evidence-based product development in natural health sector and American Botanical Council announce database intended to help consumers, researchers and health care professionals make natural product choices based on specific scientific and clinical evidence.
FDA schedules public meeting for 19 November to discuss sex and gender differences in the use and response to cannabidiols. The meeting will address the issue of CBD use in pregnancy, for which no human data currently is available.
In report to Congress about determining an enforcement discretion policy for CBD-containing non-drug products, FDA described challenges it faces, largely unique in its history, in determining whether hemp-derived ingredients are safe in food, supplements and other products that already are “sold increasingly widely."